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Abstract
 
Decoy receptor 3 (DCR3) halts both Fas ligand– and LIGHT-induced cell deaths, which are
required for pancreatic 
 
  
 
cell damage in autoimmune diabetes. To directly investigate the
therapeutic potential of DCR3 in preventing this disease, we generated transgenic nonobese
diabetic mice, which overexpressed DCR3 in 
 
  
 
cells. Transgenic DCR3 protected mice from
autoimmune and cyclophosphamide-induced diabetes in a dose-dependent manner and signifi-
cantly reduced the severity of insulitis. Local expression of the transgene did not alter the diabe-
togenic properties of systemic lymphocytes or the development of T helper 1 or T regulatory
cells. The transgenic islets had a higher transplantation success rate and survived for longer than
wild-type islets. We have demonstrated for the first time that the immune-evasion function of
DCR3 inhibits autoimmunity and that genetic manipulation of grafts may improve the success
and survival of islet transplants.
Key words: NOD • Fas ligand • LIGHT • T helper 1 cell • T regulatory cell
 
Introduction
 
Decoy receptor 3 (DCR3), also known as TR6 or M68,
was cloned from the human-expressed sequence tag data-
base because its conserved sequences belong to the TNFR
superfamily. DCR3 lacks the transmembrane domain of
conventional TNFRs and is believed to be a secreted protein.
Elevated DCR3 expression is observed in many kinds of
tumors, including lung and colon cancers (1), gastrointestinal
tumors (2), and malignant glioma (3). Elevated DCR3
expression might benefit tumors by helping them avoid
immune attacks by lymphocyte infiltration and Fas ligand
(FasL)/LIGHT-mediated apoptosis. Although the biological
significance of DCR3 is not fully understood, DCR3
clearly interacts with FasL (1), LIGHT (4), and TNF-like
molecule 1A (TL1A; reference 5), and neutralizes the apop-
totic signals through Fas receptor, lymphotoxin 
 
  
 
receptor
(LT
 
 
 
R), and death receptor 3, respectively. DCR3 also
serves another regulating function by directly modulating
the differentiation and function of dendritic cells and macro-
phages (6, 7). Moreover, DCR3 ameliorates the rejection
response to mouse heart allograft (8). Because development
of autoimmune diabetes requires lymphocyte infiltration
into islets and 
 
  
 
cell apoptosis mediated by FasL (9, 10) and
LIGHT (11, 12), we evaluated the therapeutic potential of
DCR3 in an organ-specific transgenic mouse model.
The nonobese diabetic (NOD) mouse is an inbred strain
that spontaneously develops autoimmune diabetes, which
resembles human type 1 diabetes (13, 14) and is characterized
by progressive autoimmune destruction of the insulin-
producing 
 
  
 
cells in the pancreatic islets of Langerhans.
Both genetic predisposition and environmental factors con-
tribute to the pathogenesis of autoimmune diabetes. NOD
serves as an important model for dissecting immunopatho-
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logical mechanisms and designing preventive and therapeu-
tic strategies in type 1 diabetes.
To explore the therapeutic potential of DCR3 to prevent
autoimmune diseases, we generated transgenic NOD mice,
which overexpressed DCR3 in their 
 
  
 
islets. Our results in-
dicate that islet-specific expression of DCR3 not only pro-
tects 
 
 
 
 cells from autoimmune or chemical-induced destruc-
tion, but also improves the transplantation success rate and
prolongs the survival period after transplantation. Our data
also show that islet-restricted expression of DCR3 does not
alter the integrity of islets and is not likely to induce any ab-
normal phenotype or overgrowth activity seen in tumor
cells, which can harm transgenic mice. More importantly, in
NOD mice, local expression of DCR3 did not affect sys-
temic immune responses, such as T cell–mediated diabeto-
genesis, Th1 differentiation, and T regulatory cell (Treg) devel-
opment, indicating that the therapeutic potential is restricted
and organ specific. We have shown for the first time that the
immune-escaping property of DCR3 can apply to organ-
specific autoimmunity and that this genetic modification of
 
  
 
cells improves the survival of transplanted islets. This may
contribute to alleviating the rejection response common in
allogenic islet transplantation in autoimmune diabetes.
 
Materials and Methods
 
Mice.
 
NOD/Sytwu (K
 
d
 
, D
 
b
 
, L
 
d
 
, I-A
 
g7
 
) and NOD/SCID
mice were purchased from The Jackson Laboratory and subse-
quently bred at the Animal Center of the National Defense Med-
ical Center in Taipei, Taiwan, under specific pathogen-free con-
ditions. The spontaneous incidence of diabetes in the colony was
80–90% in females and 20–30% in males by 25 wk of age. The
linear DNA fragment (see Fig. 1 a) was microinjected into the
pronuclei of one-cell NOD embryos.
 
Detection of DCR3 Transgene.
 
Genomic DNA was prepared
and hybridized with DCR3 cDNA (sequence data are available
from GenBank/EMBL/DDBJ under accession no. AF104419).
TRIzol reagent (Invitrogen) was used to extract pancreatic RNA
and protein. Isolated RNA was reverse transcribed by Superscript
II reverse transcriptase (Invitrogen) with the backward primer
5
 
 
 
-TAGGTGGGTGTTTCTGCCAC-3
 
 
 
, and amplified by the
PCR reaction together with the forward primer 5
 
 
 
-GGATCCT-
GAGAACTTCAGG-3
 
  
 
at an annealing temperature of 58
 
 
 
C for
30 cycles. PCR examination of genomic DNA was performed
with the same primers described above and internally controlled
with another pair of primers, 5
 
 
 
-ATCTCCTACCCCAAAC-
CTC-3
 
  
 
and 5
 
 
 
-ACCATCTTTCCCCTCTTCC-3
 
 
 
. To stan-
dardize the amount of mRNA in each sample, the RT-PCR
product of 
 
hgprt
 
 was detected by the forward primer 5
 
 
 
-CTC-
GAAGTGTTGGATACAGG-3
 
  
 
and backward primer 5
 
 
 
-
TGGCCTATAGGCTCATAGTG-3
 
 
 
. Western blot analysis was
probed by primary mouse monoclonal antibody against human
DCR3 (Anawrahta) and then detected with horseradish peroxi-
dase–conjugated goat anti–mouse Ig antibody and ECL reagent
(Amersham Biosciences).
 
Immunohistochemical Analysis.
 
The pancreas was removed from
each mouse and fixed with periodate-lysine-paraformaldehyde.
Sections of each sample were probed with biotin-conjugated
anti-DCR3 monoclonal antibody (Anawrahta) followed by strepta-
vidin horseradish peroxidase, and then stained with AEC reagent
(DakoCytomation) for 10 min. In another experiment, transgenic
islet-bearing kidneys were removed from mice at different time
points after transplantation and the graft sections were fixed and
further stained for DCR3 or insulin (guinea pig anti–porcine in-
sulin; DakoCytomation) as described above.
 
Assessment of Insulitis and Diabetes.
 
The severity of insulitis was
scored on hematoxylin- and eosin-stained sections of pancreas
from mice 14–16 wk of age. Investigators were blind to the iden-
tity of the sections. At least 50 islets from each pancreas were
randomly chosen for microscopic examination. Severity of insuli-
tis was classified as previously described (15). Urine glucose con-
centration was measured weekly using Chemstrips (Boehringer).
Animals that scored positively (
 
 
 
250 mg/dL) on two consecu-
tive tests were classified as diabetic. In some experiments, groups
of mice were treated intraperitoneally with 200 mg/kg cyclo-
phosphamide twice at the ages of 8 and 9 wk to accelerate dia-
betic process, and then the urine glucose concentration was mea-
sured every other day for 4 wk.
 
T Cell Proliferation.
 
Splenocytes from 8-wk-old mice were
treated with Tris-buffered ammonium chloride to eliminate the
erythrocytes, washed, and resuspended at a cell concentration of
2.5 
 
  
 
10
 
6
 
/ml in RPMI 1640 supplemented with 1% Nutridoma-
Figure 1. Generation of transgenic mice. (a) Schematic diagram of the
whole transgene construct. The black areas represent exons and the gray
areas represent introns. The entire first noncoding exon followed by the
first intron and 16 bp of the second exon of human insulin gene, which
are not translated into protein, were preserved to ensure the stringency of
the insulin promoter. To enhance the expression of the transgene in this
construct, the introns of rabbit  -globin gene were introduced adjacent to
these. A forward primer located in the second exon of the insulin gene
(top arrow) and a backward primer in the coding region of DCR3 (bottom
arrow) were designed to determine the transcription of transgene in RT-
PCR and to detect the existence of DCR3 transgene from genomic
PCR. (b) Southern blot analysis proved the transgenic DCR3 signals in
PD7 and PD8 founders and provided the relative copy number of each
transgenic line, indicated by the solid arrow. (c) The transgene detected
by genomic PCR analysis is indicated by the solid arrow and the internal
control of IL-12 p35 is indicated by the dashed arrow. (d) The spliced
transcript of transgenic DCR3 determined by pancreatic RT-PCR is
indicated by the solid arrow and internal control of hgprt is indicated by
the dashed arrow. (e) DCR3 protein was detected by Western blot of
pancreatic extracts (solid arrow). Actin signals served as a control (dashed
arrow). (f) Tissue-specific expression of the transgene was confirmed by
RT-PCR analysis of multiple organs. The positive signal of DCR3 tran-
script appeared only in pancreas (solid arrow). hgprt transcripts are internal
controls (dashed arrow). 
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SP (Boehringer; reference 16). Cells were stimulated with syn-
thetic GAD peptides (p524–543; reference 17) or control ovalbu-
min peptide (p323–336). The incorporated [
 
3
 
H]methyl thymi-
dine was detected with TopCount (Packard Instrument Co.).
SEM was 
 
 
 
15% of the mean.
 
Adoptive Transfer.
 
Spleens of female transgenic or nontrans-
genic NOD donors were removed at 13 wk, erythrocytes were
depleted with Tris-buffered ammonium chloride, and 2 
 
  
 
10
 
7
 
cells were injected into 8-wk-old female NOD/SCID via the
retro-orbital plexus. Diabetes was assessed as described above. In
another experiment, 10-wk-old female transgenic NOD mice or
their nontransgenic control littermates were selected as recipients
and injected with 2 
 
  
 
10
 
7 
 
cells from 14-wk-old female NOD do-
nors with the same procedure as described above. Diabetes was
then followed as described above.
 
Flow Cytometry.
 
Splenocytes of doubly or triply transgenic
mice were stained with anti–mouse CD4 (L3T4, clone RM4-5),
anti–mouse CD8
 
  
 
(Ly2, clone 53-6.7), anti–mouse CD45R:
B220 (clone RA3-6B2), anti–mouse CD25 (clone PC61), anti–
human CD90 (hThy1, clone 5E10), and anti–mouse CD90.1
(mThy1.1, clone OX-7). Flow cytometric analysis was per-
formed with a FACSCalibur™ (BD Biosciences).
 
Islet Transplantation.
 
Pancreatic islets were isolated from mice
at 6 wk by the standard collagenase digestion method (18).
Wild-type female NOD mice that spontaneously developed dia-
betes within 1 wk were collected as recipients. 600 isolated islets
were transplanted under the left renal capsule of diabetic recipi-
ents. After transplantation, recipients’ blood glucose concentra-
tion was monitored every day, and the transplantation procedure
was considered a success when the nonfasting blood glucose
concentration returned to normal (
 
 
 
11.1 mM) on 2 consecutive
days. The survival of islets corrects hyperglycemia and the rejec-
tion of islets leads to recurrence of diabetes in recipients. The re-
currence of diabetes among the recipients was defined as a blood
glucose concentration 
 
 
 
16.7 mM in two consecutive evalua-
tions. The day of diabetic recurrence was considered the end of
islet survival.
 
Results
 
Generation of Transgenic Mice.
 
To study the organ-spe-
cific protection of DCR3 against autoimmune diabetes, we
generated the transgenic mice by injecting DNA construct
(Fig. 1 a) into fertilized NOD eggs. This construct contained
the insulin promoter, the first and partial second noncoding
exons of 
 
insulin
 
, an intron from rabbit 
 
  
 
globin
 
, human
 
DCR3
 
, and a poly A signal of rabbit 
 
  
 
globin
 
. The expression
of the 
 
DCR3
 
 transgene was controlled by the human insulin
promoter (
 
P
 
Ins
 
), which is highly specific to the pancreas and
Figure 2. Reverse correlation
of transgene expression and sever-
ity of insulitis. Immunohistochem-
ical analysis of DCR3 on pancre-
atic sections was performed on
wild-type (a), PD7 (b and c), and
PD8 mice (e and f). Differential
level of DCR3 expression was
observed on islets of PD7 (low
expression; b and c) and PD8
mice (high expression; e and f),
in agreement with the results of
RT-PCR and Western blot anal-
ysis shown in Fig. 1. Hematoxylin
and eosin staining of islets from
PD7 mice (g–i) displayed variable
degrees of insulitis at the age of
12 wk, whereas islets of PD8
mice of the same age (k and l)
were nearly free of infiltration
and maintained their integrity.
Cumulative results of insulitis
severity  were classified and
scored (j) as follows: intact islets,
without infiltrating cells (open
bars); peri-insulitis,  25% of the
area of an islet was occupied by
infiltrating cells (hatched bars);
intra-insulitis,   25 and  50%
(gray bars); severe insulitis;  50%
(bar with crisscross pattern); and
destructive insulitis, whole islet
was occupied (solid bar). Data
represent five individual PD8
mice (each bar for one transgenic
mouse, from left, 1–5) and aver-
aged results from six nontrans-
genic littermates (right) at the age
of 14 wk. Bar, 0.05 mm. 
Protective Role of Decoy Receptor 3 in Autoimmune Diabetes
 
1146
leads to good levels of protein production (19, 20). To de-
termine the transcription of the transgene and to distinguish
any possible PCR or RT-PCR products from potential mu-
rine homologues of 
 
DCR3
 
, we designed a forward primer
that locates to the second exon of the 
 
insulin
 
 gene (Fig. 1 a,
top arrow) and a backward primer that locates to the coding
region of 
 
DCR3
 
 (Fig. 1 a, bottom arrow).
Two lines of 
 
P
 
Ins
 
-DCR3 transgenic NOD mice, denoted
as pancreatic DCR3 (PD)7 and PD8, were obtained within
two independent microinjections. Southern blot analysis
revealed that PD7 carries 
 
 
 
10–15 and PD8 carries 
 
 
 
1–5
copies of the transgene in their genomes (Fig. 1 b) and that
transgenic mice could be distinguished from their non-
transgenic littermates by genomic PCR (Fig. 1 c). Al-
though PD7 mice had more copies of the transgene in-
serted in the genome, they expressed lower levels of both
RNA (Fig. 1 d) and protein (Figs. 1 e and 2, b, c, e, and f)
than PD8 mice. Transgene-based and islet-specific expres-
sion of 
 
DCR3
 
 was further confirmed by RT-PCR (Fig. 1
f) and immunohistochemical staining (Fig. 2, a–c, e, and f).
Except for the transgenic pancreas, none of the organs
tested (liver, spleen, brain, intestine, muscle, kidney, lung,
thymus, heart, ovary, and oviduct) from the transgenic
mice transcribed RNA or expressed protein of DCR3, nor
did islets from wild-type NOD mice. These results strongly
indicate that the expression of DCR3 is strictly transgene
based and islet specific.
 
Transgene Expression and the Disease Process.
 
To investi-
gate the idea that higher expression of transgenic DCR3
may render stronger protection, we compared the severity
of insulitis and spontaneous or chemical-induced disease
incidence between PD7 and PD8 mice. High expresser
PD8 mice expressed transgene in a diffuse and extended
manner throughout nearly the entire islet (Fig. 2, e and f).
In contrast, PD7 mice secreted DCR3 in a spot-like pat-
tern within limited areas (Fig. 2, b and c). Expression of the
transgene in islets significantly ameliorated the severity of
insulitis, especially in PD8 mice (Fig. 2 j). Interestingly,
mononuclear cell infiltration was lower in areas expressing
high levels of DCR3 in transgenic islets than in areas with
lower levels of transgene expression. This was consistent
with the observation that low expresser PD7 mice still ex-
hibit variable degrees of insulitis (Fig. 2, g–i), whereas high
expresser PD8 mice are almost free from insulitis (Fig. 2,
j–l). This inverse correlation between DCR3 expression
and insulitis severity is supported by previous data showing
that DCR3 by itself can counteract FasL-mediated chemo-
taxis and therefore reduce the infiltration of immune cells
in gliomas (3). Moreover, a recent study demonstrated that
reverse signaling through LIGHT could also inhibit T cell
chemotaxis both in vitro and in vivo (21).
To further investigate the efficacy of the protection of
transgenic DCR3 in PD7 and PD8 mice, we compared the
incidence of diabetes in spontaneous or chemical-induced
disease (Fig. 3). PD7 mice developed less severe diabetes
than their nontransgenic littermates (P 
 
  
 
0.05), suggesting
that weak transgenic expression of DCR3 mediates a cer-
tain degree of protection (Fig. 3 a). More importantly, PD8
mice with higher DCR3 expression were completely pro-
tected from developing autoimmune diabetes (P 
 
  
 
0.01),
demonstrating the strong immunoprotective potential of
DCR3 in an organ-specific manner (Fig. 3 b). Similarly,
transgenic DCR3 protected mice from cyclophosphamide-
induced diabetes in a dose-dependent manner (Fig. 3 c).
After two shots of cyclophosphamide injection (200 mg/
kg) at the ages of 8 and 9 wk, all control NOD mice be-
came diabetic within 3 wk, whereas only 50% of PD7 (P 
 
 
 
0.05) and none of the PD8 mice (P 
 
  
 
0.01) became dia-
Figure 3. Spontaneous and chemical-induced diabetes in transgenic
mice. Female transgenic mice and their control littermates were moni-
tored by weekly measurements of glycosuria and blood sugar for sponta-
neous diabetic incidence (a and b). There were 18 PD7 mice ( ) and 24
nontransgenic littermates ( ). a, Kaplan-Meier method, P   0.05. There
were 22 PD8 mice ( ) and 21 control littermates ( ). b, P   0.01. Fre-
quency of chemical-induced diabetes by two shots of cyclophosphamide
(indicated by arrows at days 0 and 7) was monitored in PD7 ( , n   12,
P   0.05), PD8 ( , n   12, P   0.01), and nontransgenic control mice
( , n   16).Sung et al. 1147
betic. We further observed that none of the PD8 mice, re-
gardless of sex, developed diabetes at any age thus far stud-
ied, even those older than 70 wk or throughout pregnancy
and several breeding cycles (unpublished data). Our results
indicate that sufficient expression of DCR3 strongly pro-
tects islets from autoimmune or chemical-induced destruc-
tion and completely prevents development of diabetes. The
difference in protection between PD7 and PD8 mice does
not arise simply by random integration of transgenes be-
cause the protective efficacy between these lines displays a
dose-dependent manner and correlates with the quantity of
transgenic DCR3 expression in islets.
Diabetogenic Properties of T Cells from Transgenic Mice.
Our data showed that transgenic DCR3 in PD8 mice com-
pletely protected them from either spontaneous or cyclo-
phosphamide-induced diabetes. To investigate whether the
protective mechanism works through down-regulation of
diabetogenic T cells, we examined the GAD65-specific T
cell response in PD8 mice. GAD65 is one of the key au-
toantigens in insulin-dependent diabetes mellitus (IDDM).
8-wk-old PD8 mice exhibited levels of T cell proliferative
responses to synthetic GAD65 peptide (524–543) similar to
those observed in age-matched control NOD mice (Fig. 4
a). This result indicates that PD8 mice protected from au-
toimmune diabetes retain a significant autoantigen-specific
T cell response. To further examine the diabetogenic ability
of PD8 lymphocytes, we performed an adoptive transfer
experiment in the NOD/SCID system. We isolated lym-
phocytes from PD8 mice or their nontransgenic littermates
at the age of 13 wk and transferred these cells into NOD/
SCID mice. The two groups of recipients developed diabe-
tes with similar onset, diabetic process, and severity (Fig. 4
b). This result clearly indicates that DCR3 most likely pro-
tects islets in situ instead of down-regulating the diabetoge-
nicity of lymphocytes by systematically altering T cell func-
tion in PD8 mice. To further investigate this point, we
performed another adoptive transfer experiment. Spleno-
cytes from female diabetic NOD mice were transferred into
DCR3 transgenic mice or their control littermates. 4 of 6
control recipients became diabetic within 3 wk after trans-
fer, whereas none of the 11 transgenic recipients developed
diabetes (P   0.05; Fig. 4 c). This result further confirms
that expression of DCR3 transgene in situ effectively pro-
tects islets from destruction by diabetogenic splenocytes.
This organ-specific modulation is further supported by our
recent findings that soluble DCR3 is barely detectable in
the circulation of transgenic mice (unpublished data).
Development of Th1 and Treg Cells in Transgenic Mice.
An imbalance between Th1 and Th2 responses predisposes
NOD mice to developing autoimmune diabetes (22, 23).
To investigate whether down-regulation of Th1 effector
cells or induction of Th2 cells protects against diabetes in
PD8 mice, we crossed PD8 transgenic mice with T1 and
T2 doubly transgenic mice, and monitored the develop-
ment of Th1 or Th2 cells in these triply transgenic NOD
mice. Originally from a BALB/c background, T1 and T2
doubly transgenic mice bear two transgenes, which express
two distinct cell surface markers: one human Thy1 trans-
gene (hThy1) under control of the murine IFN-  pro-
moter, and one murine Thy1.1 (mThy1.1) under control
Figure 4. Diabetogenic properties of T cells from transgenic mice.
(a) GAD65-specific T cell response in PD8 mice. Splenocytes from 8-wk-
old female PD8 (two individual mice are indicated as gray and solid bars)
and nontransgenic control (open bars) mice were stimulated with GAD65
antigenic peptide p524–543 or control peptide ovalbumin p323–336 in
vitro. The incorporated [3H]methyl thymidine was detected with Top-
Count. SEM was  15% of the mean. (b) Adoptive transfer of lympho-
cytes of PD8 mice. Splenocytes from 13-wk-old female PD8 mice ( ) or
their nontransgenic littermates ( ) were intravenously transferred into
NOD/SCID mice. Recipients were monitored for diabetes by weekly
measurements of glycosuria and blood sugar. The number of recipients
for PD8 and control mice was 10 and 8, respectively. (c) Protection from
diabetogenic lymphocyte-transferred disease. Splenocytes from 14-wk-
old female diabetic NOD donors were intravenously transferred into
10-wk-old female transgenic NOD mice ( ) or their nontransgenic control
littermates ( ). Recipients were monitored for diabetes every other day by
measurements of glycosuria and blood sugar. The number of transgenic
recipients and control mice was 11 and 6, respectively.Protective Role of Decoy Receptor 3 in Autoimmune Diabetes 1148
of the murine IL-4 promoter. We designated these as T1
and T2 transgenes, respectively (24). These doubly trans-
genic mice were backcrossed to NOD mice for more than
12 generations, which provided the best model to study the
differentiation of helper or cytotoxic T cell subsets during
the diabetogenic process in IDDM. In the spleen or pan-
creatic lymph node, the absolute cell number and lympho-
cyte subpopulation distribution were similar in regular and
triply transgenic NOD mice, indicating that transgenic
DCR3 in islets does not affect lymphocyte development in
peripheral lymphoid organs (Fig. 5, a and b, left). Interest-
ingly, the number and percentage of IFN- –producing
(hThy1 ) or IL-4–producing (mThy1.1 ) cells of spleen or
pancreatic lymph node in triply transgenic mice were not
different from those observed in doubly transgenic mice
(Fig. 5, a and b, right), suggesting that transgenic DCR3
in islets does not suppress the development of systemic
IFN- –producing or induce IL-4–producing cells in mice.
However, the pancreatic lymph node, but not the spleen,
of triply transgenic mice had significantly fewer Th1 cells
(CD4  hThy1 ) than that of doubly transgenic mice. This
result further confirms the essential role of Th1 cells in
IDDM. These data also suggest that Th1 cell number in
pancreatic lymph node in DCR3 transgenic mice declines
because of significantly reduced infiltration of mononuclear
cells in nearby islets. The similar populations of Th1 cells in
spleens in triply and doubly transgenic mice further suggest
that DCR3-mediated protection is more likely to occur
through modulating local rather than systemic effects.
NOD mice have a relative deficiency of CD4  CD25 
Tregs, which could cause an inability to maintain pe-
ripheral tolerance (25). To investigate whether transgenic
DCR3 mice can generate these regulatory cells and protect
PD8 mice from autoimmune diabetes, we compared the
number and percentage of CD4  CD25  cells in transgenic
and control mice. PD8 transgenic mice and their nontrans-
genic littermates exhibited similar numbers and percentages
of CD4  CD25  cells in the spleen and pancreatic lymph
node (Fig. 5, a and b, right), suggesting that the protective
effect of DCR3 is not likely to be mediated by inducing
the population of Tregs.
Transplantation of Transgenic Islets. DCR3 protein can ame-
liorate the rejection response to a mouse heart allograft and
reduce the primary nonfunction of an islet isograft (26). A
stringent way to test whether overexpression of DCR3
could protect   cells against immune attack is to examine
whether transgenic islet grafts could reverse diabetes in
spontaneously diabetic mice. We isolated islets from PD8
mice and transplanted them into kidney capsules of diabetic
NOD recipients. DCR3-secreting islets had a higher rate of
successful transplantation and survived for longer than wild-
type islets (9.1 and 3.1 d, respectively; P   0.05; Table I).
To further investigate whether transplantation processes dis-
turb the transgene expression and how long transgenic islets
continue to express DCR3, we examined the production
of DCR3 in graft islets by immunohistochemical staining.
Transgenic islet grafts from mice at day 6 after transplanta-
tion still expressed DCR3 with preservation of islet architec-
ture (Fig. 6 a). However, as compared with pancreatic islets
in PD8 mice, islet grafts from transplanted mice showed a
different expression pattern. In contrast to a diffuse and ex-
tended manner throughout nearly the entire pancreatic islet
(Fig. 2, e and f), DCR3 expression in islet graft was signifi-
cantly diminished and limited in central area (Fig. 6 a). In-
terestingly, the area of DCR3-producing cells was almost
confined to that of insulin-secreting cells (Fig. 6 b), suggest-
ing a coexpression of these two proteins in graft islets. How-
ever, these transgenic islets were destroyed by autoimmune
Figure 5. Development of Th1
and Treg cells in transgenic
mice. The composition of lym-
phocytes in spleen (a, left) and
pancreatic lymph node (b, left)
was analyzed by flow cytometry
from 10–14-wk-old mice (triply
transgenic mice are indicated
with the solid bars, and control
mice are indicated with the open
bars). Th1 (CD4  hThy1 ) and
Treg (CD4   CD25 ) cells in
spleen (a, right) and pancreatic
lymph node (b, right) were further
analyzed from triply (solid bars)
or doubly (open bars) transgenic
mice. Data represent five inde-
pendent experiments and stan-
dard errors were calculated.Sung et al. 1149
attack after longer days. Islet grafts removed from mice 20 d
after transplantation showed a massive mononuclear cell in-
filtration with disrupted islet architecture (Fig. 6 c). In sum-
mary, expression of transgenic DCR3 was potentially effec-
tive in prolonging islet graft survival, but did not provide
permanent protection from diabetes recurrence.
Discussion
The biological function of DCR3 is still being evaluated.
Its natural ligands include FasL (1), LIGHT (4), TL1A (5),
and unknown molecules present on certain antigen-pre-
senting cells such as dendritic cells and macrophages (6, 7).
Studies have increasingly focused on the best-characterized
function: the ability of DCR3 to counteract FasL/LIGHT-
mediated apoptosis (1, 4) and block FasL-mediated che-
motaxis (3, 21). Our data are the first to demonstrate that
islet-restricted expression of DCR3 in NOD mice pro-
tects them from chemical-induced or autoimmune diabetes.
This organ-specific modulation does not appear to affect
systemic T cell development and function. Moreover, the
transgenic islets had a higher transplantation success rate
and survived for longer than control islets, suggesting a po-
tential of DCR3 in organ transplantation.
The role of Fas in autoimmune diabetes is still contro-
versial. Both NOD-lpr/lpr (deficient in Fas; reference 27)
and NOD-gld/gld (deficient in FasL; reference 10) mice are
free from insulitis and diabetes, suggesting a pathogenic
role of Fas in   cell destruction. However, the difficulty in
detecting Fas on the surface of   cells in NOD mice com-
plicates understanding the role of Fas in autoimmune dia-
betes (28). One report demonstrated that the expression of
Fas on   cells was induced by lymphocytes infiltrating into
islets, supporting its pathogenic role in autoimmune diabe-
tes (9). Another more recent study using rat insulin pro-
moter–driving dominant negative Fas transgenic NOD
mice revealed that early interference in the Fas pathway of
the disease process could retard or even prevent autoim-
mune diabetes (29). These data indicate that although  
cells do not physiologically express Fas, the Fas-mediated
pathway still plays an initial and subsequent role in   cell
destruction when triggered by the autoimmune diabetoge-
nic process. Moreover, transgenic expression (11) or treat-
ment with LT R–Ig fusion protein (12), which blocks the
native interaction between LT R and LIGHT, could also
inhibit the diabetic process in NOD mice. The observation
that PIns-DCR3 transgenic NOD mice exhibit the same
phenotype supports this concept. Our data suggest two
possible mechanisms underlying DCR3-mediated protec-
tion. First, islet-specific expression of DCR3 may neutral-
ize chemotaxis induced by soluble FasL, which is secreted
by mononuclear cells infiltrating into islets in situ. There-
fore, we observed significant depression of the insulitis
score in PD8 mice. Second, DCR3 may counteract   cell
apoptosis directly caused by FasL- or LIGHT-bearing cells
that infiltrate into islets, thereby protecting the integrity
and function of islets.
Although NOD-lpr/lpr mice are completely protected
from insulitis and diabetes, islets from these mice survive
only slightly longer than wild-type islets after transplanta-
tion into diabetic recipients (28). This indicates that other
killing mechanisms, such as cytokine-induced apoptosis
(30), perforin-mediated cytotoxity (31), or elevated oxida-
tive stress (20, 32), may damage islet grafts in diabetic re-
cipients. Interestingly, our transplantation results revealed
that DCR3-secreting islets were maintained without any
treatment after surgery, indicating that in contrast to Fas-
deficient islets, DCR3 protects islets and prolongs graft sur-
Table I. Transgenic DCR3 Enhances the Success Rate and 
Prolongs the Survival Period of Grafts in Isogenic Islet Transplantation
Donor PD8 mice Control mice p-value
Number of recipients 20 16 —
Number of successes 13 6 —
Success rate 65% 38% —
Mean survival period (days) 9.1 3.1  0.05
Pancreatic islets isolated from 6-wk-old mice were transplanted into
recipients that were newly diagnosed with diabetes. Recipients’ blood
glucose concentration was monitored every day and the transplantation
procedure was considered a success when the nonfasting blood glucose
concentration returned to normal ( 11.1 mM) for 2 consecutive days
after transplantation. The recurrence of diabetes among the recipients
was defined as a recipient blood glucose concentration  16.7 mM in
two consecutive evaluations. The day of diabetic recurrence was
considered the end of islet survival.
Figure 6. Transgene expression
in graft islets. (a) DCR3 expression
in early stage after transplantation.
Transgenic islet graft-bearing
kidneys were removed from
mice 6 d after transplantation and
immunohistochemically stained
for DCR3. (b) Insulin expression
in early stage after transplantation.
Transgenic islet graft-bearing
kidneys were removed from
mice 6 d after transplantation and
immunohistochemically stained for insulin. (c) Transgene expression in late stage after transplantation. Transgenic islet graft-bearing kidneys were
removed from mice 20 d after transplantation and immunohistochemically stained for DCR3 and insulin. Bar, 0.05 mm.Protective Role of Decoy Receptor 3 in Autoimmune Diabetes 1150
vival from active immune attack in diabetic recipients. We
suggest that this results from the secreting function of
DCR3 or the net effect of its biological functions other
than the FasL- or LIGHT-neutralizing property because
DCR3 modulates the local or systemic immune responses
by interacting with FasL, LIGHT, TL1A, and other un-
known ligands. It is also important that Fas-independent
pathways contribute to autoimmune destruction and even-
tually eliminate both Fas-deficient (28) and DCR3-secret-
ing islet grafts. In our transplantation model, the failure of
long-term graft survival correlated with the reduction of
DCR3 expression. This may imply two possibilities. One
possible explanation might be that insulin promoter–driving
expression of DCR3 was disturbed by the primary non-
function of transplanted islets. Another possible explanation
is that transplantation processes trigger strong oxidative
stress- or cytokine-induced apoptosis of transplanted islets,
which cannot be blocked by DCR3. Nevertheless, our
data still provide a new aspect for designing preventive and
therapeutic approaches to islets or other transplants, which
escape from autogenic, allogenic, or even xenogenic im-
mune responses.
Unlike islet-specific expression of TGF-  in transgenic
NOD mice, which results in smaller-sized islets (33, 34),
DCR3 does not alter the nature and integrity of islets. Both
cases described above can effectively protect these mice
from autoimmune diabetes, however, lymphocytes from
TGF-  transgenic mice are less able to induce diabetes after
transfer into NOD/SCID mice. Therefore, the protective
effects of TGF-  tend to influence the diabetogenicity of
lymphocytes rather than local events. Recent studies of
DCR3 demonstrate that the native form of this protein
does not exist in the mouse circulation for long enough to
bind FasL (35, 36), supporting our conclusion that the
DCR3-mediated protection is mainly a local effect. This is
consistent with our inability to detect soluble DCR3 in
sera from PD8 mice by sandwich ELISA, although we can-
not completely rule out the existence of undetectable
amounts of DCR3 in the circulation.
Our experiments demonstrate that systemic T cell phe-
notype and function are maintained in DCR3 transgenic
mice. The specific T cell properties maintained include T
cell subpopulations, Th1 or Treg cell development, au-
toantigen-specific immune response, and diabetes transfer
ability. We believe that the decrease in the Th1 population
in pancreatic lymph nodes is an outcome of reduced insuli-
tis rather than a causal factor that mediates protection. Our
results indicate that transgenic DCR3 most likely protects
islets in situ rather than by influencing the polarizations of
immune responses or induction of Tregs through the cir-
culation. Our data suggest that graft-restricted expression of
DCR3 may provide additional advantages without disturb-
ing the immune system in recipients.
The mouse homologue of human DCR3 has not yet
been identified. Our experiments explored the biological
significance and potential application of DCR3 in immune
evasion, which occurs in tumor cells and applies to the tis-
sue-specific, autoimmune attack model. DCR3 has other
biological effects besides escape from the immune system.
In the human and mouse, DCR3 participates in other im-
mune regulatory functions, such as modulation of dendritic
cell and macrophage functions through unknown ligands.
We believe that the biological function and physiological
role of DCR3 might be more extensive than currently
known. Further understanding of the biological function of
DCR3 may contribute to development of therapeutic
strategies in immune or other diseases.
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